



CMV pp65 (3A12): sc-56973

BACKGROUND

Cytomegalovirus (CMV) is a member of the herpes virus group which includes herpes simplex virus types 1 and 2; Varicella Zoster Virus, which causes chicken pox; and Epstein Barr virus, which causes infectious mononucleosis. These viruses remain dormant within the body over a long period. In humans, CMV is known as HCMV or human herpesvirus 5 (HHV-5). HHV-5 causes only a brief mononucleosis-like malaise in immunocompetent adults, but may cause severe illness or death in immunosuppressed individuals. CMV pp65 is the early-late lower matrix phosphoprotein of CMV that may be relevant to the etiopathogenesis of scleroderma. CMV pp65 is a major constituent of the CMV virion bodies and is abundantly synthesized during lytic infection. In addition, the CMV pp65 protein is a frequent target for the exceptionally strong CMV-specific CD8⁺ T cell response.

REFERENCES

1. Margraf, S., Bittoova, M., Vogel, J.U., Kotchekov, R., Doerr, H.W. and Cinatl, J. 2001. Antisense oligonucleotide ISIS 2922 targets IE-expression and prevents HCMV suppression of TSP-1 and TSP-2 expression. *Nucleosides Nucleotides Nucleic Acids* 20: 1425-1428.
2. Khan, N., Cobbold, M., Keenan, R. and Moss, P.A. 2002. Comparative analysis of CD8⁺ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. *J. Infect. Dis.* 185: 1025-1034.
3. Snaar, S.P., Verdijk, P., Tanke, H.J. and Dirks, R.W. 2002. Kinetics of HCMV immediate early mRNA expression in stably transfected fibroblasts. *J. Cell Sci.* 115: 321-328.
4. Vlasák, J., Smahel, M., Pavlík, A., Pavingerová, D. and Bríza, J. 2003. Comparison of hCMV immediate early and CaMV 35S promoters in both plant and human cells. *J. Biotechnol.* 103: 197-202.
5. McGregor, A., Liu, F. and Schleiss, M.R. 2004. Molecular, biological, and *in vivo* (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). *J. Virol.* 78: 9872-9889.
6. Moss, P. and Khan, N. 2004. CD8⁺ T cell immunity to cytomegalovirus. *Hum. Immunol.* 65: 456-464.
7. Carlsson, B., Hou, M., Giandomenico, V., Nilsson, B., Totterman, T.H. and Essand, M. 2005. Simultaneous generation of cytomegalovirus-specific CD8⁺ and CD4⁺ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein. *J. Infect. Dis.* 192: 1912-1920.
8. Sinici, I., Zarghooni, M., Tropak, M.B., Mahuran, D.J. and Ozkara, H.A. 2006. Comparison of HCMV IE and EF-1 promoters for the stable expression of β subunit of hexosaminidase in CHO cell lines. *Biochem. Genet.* 44: 173-180.
9. Nambodiri, A.M., Rocca, K.M., Kuwana, M. and Pandey, J.P. 2006. Antibodies to human cytomegalovirus protein UL83 in systemic sclerosis. *Clin. Exp. Rheumatol.* 24: 176-178.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

CMV pp65 (3A12) is a mouse monoclonal antibody raised against CMV.

PRODUCT

Each vial contains 100 μ g IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

CMV pp65 (3A12) is recommended for detection of pp65 of CMV origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of CMV pp65: 65 kDa.

SELECT PRODUCT CITATIONS

1. Tang, Q., Roan, N.R. and Yamamura, Y. 2013. Seminal plasma and semen amyloids enhance cytomegalovirus infection in cell culture. *J. Virol.* 87: 12583-12591.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.